Your browser doesn't support javascript.
loading
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream.
Calabrò, Luana; Bronte, Giuseppe; Grosso, Federica; Cerbone, Luigi; Delmonte, Angelo; Nicolini, Fabio; Mazza, Massimiliano; Di Giacomo, Anna Maria; Covre, Alessia; Lofiego, Maria Fortunata; Crinò, Lucio; Maio, Michele.
Afiliación
  • Calabrò L; Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
  • Bronte G; Department of Oncology, University Hospital of Ferrara, Ferrara, Italy.
  • Grosso F; Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica Delle Marche, Ancona, Italy.
  • Cerbone L; Clinic of Laboratory and Precision Medicine, National Institute of Health and Sciences On Ageing (IRCCS INRCA), Ancona, Italy.
  • Delmonte A; Mesothelioma, Melanoma and Sarcoma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Nicolini F; Mesothelioma, Melanoma and Sarcoma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Mazza M; Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Di Giacomo AM; IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Covre A; IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Lofiego MF; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.
  • Crinò L; Center for Immuno-Oncology, University of Siena, Siena, Italy.
  • Maio M; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.
Front Immunol ; 14: 1333661, 2023.
Article en En | MEDLINE | ID: mdl-38259475
ABSTRACT
Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The dramatic therapeutic scenario of PM has recently changed with the entry into the clinic of immune checkpoint inhibition, which has proven to be an effective approach to improve the survival of PM patients. The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced PM.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pleurales / Mesotelioma Maligno / Mesotelioma Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pleurales / Mesotelioma Maligno / Mesotelioma Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Italia